-
-
-
-
-
-
-
BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility
-
-
-
-
-
-
-
BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer
-
-
-
-
-
-
-
BioCryst Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range
-
-
-
-
-
-
-
BioCryst to acquire Astria Therapeutics for $920 million
-
-
-
-
-
-
-
RBC Capital on BioCryst Pharma (BCRX): 'We See Shares Undervalued'
-
-
-
-
-
-
-
BioCryst Appoints Steve Frank to Board of Directors
-
-
-
-
-
-
-
BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)
-
1,219,297 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

